Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications
Abstract Treatment with statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A
reductase, has proven beneficial preventive effects on cardiovascular events. However …
reductase, has proven beneficial preventive effects on cardiovascular events. However …
[HTML][HTML] World heart federation cholesterol roadmap 2022
Background: Atherosclerotic cardiovascular diseases (ASCVD) including myocardial
infarction, stroke and peripheral arterial disease continue to be major causes of premature …
infarction, stroke and peripheral arterial disease continue to be major causes of premature …
[HTML][HTML] Polypill strategy in secondary cardiovascular prevention
JM Castellano, SJ Pocock, DL Bhatt… - … England Journal of …, 2022 - Mass Medical Soc
Background A polypill that includes key medications associated with improved outcomes
(aspirin, angiotensin-converting–enzyme [ACE] inhibitor, and statin) has been proposed as …
(aspirin, angiotensin-converting–enzyme [ACE] inhibitor, and statin) has been proposed as …
[HTML][HTML] Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label …
KK Ray, RPT Troquay, FLJ Visseren… - The Lancet Diabetes & …, 2023 - thelancet.com
Introduction Whether long-term treatment with the twice-yearly, siRNA therapeutic inclisiran,
which reduces hepatic production of proprotein convertase subtilisin/kexin type 9 (PCSK9) …
which reduces hepatic production of proprotein convertase subtilisin/kexin type 9 (PCSK9) …
Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction
Background The proprotein convertase subtilisin kexin type-9 inhibitor evolocumab
produced coronary atheroma regression in statin-treated patients. Objectives The purpose of …
produced coronary atheroma regression in statin-treated patients. Objectives The purpose of …
[HTML][HTML] Treatment gaps in the implementation of LDL cholesterol control among high-and very high-risk patients in Europe between 2020 and 2021: the multinational …
KK Ray, I Haq, A Bilitou, MC Manu… - The Lancet Regional …, 2023 - thelancet.com
Background European data pre-2019 suggest statin monotherapy is the most common
approach to lipid management for preventing cardiovascular (CV) events, resulting in only …
approach to lipid management for preventing cardiovascular (CV) events, resulting in only …
[HTML][HTML] Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial
SJ Nicholls, M Ditmarsch, JJ Kastelein, SP Rigby… - Nature medicine, 2022 - nature.com
Global guidelines for the management of high-cardiovascular-risk patients include
aggressive goals for low-density lipoprotein cholesterol (LDL-C). Statin therapy alone is …
aggressive goals for low-density lipoprotein cholesterol (LDL-C). Statin therapy alone is …
Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targeting PCSK9 in Nonhuman Primate and Mouse Models
RG Lee, AM Mazzola, MC Braun, C Platt, SB Vafai… - Circulation, 2023 - Am Heart Assoc
Background: VERVE-101 is an investigational in vivo CRISPR base-editing medicine
designed to alter a single DNA base in the PCSK9 gene, permanently turn off hepatic …
designed to alter a single DNA base in the PCSK9 gene, permanently turn off hepatic …
Inclisiran and cardiovascular events: a patient-level analysis of phase III trials
Background Inclisiran, an siRNA administered twice-yearly, significantly reduced LDL
cholesterol (LDL-C) in Phase III trials. Whether lowering LDL-C with inclisiran translates into …
cholesterol (LDL-C) in Phase III trials. Whether lowering LDL-C with inclisiran translates into …
Combination lipid-lowering therapy as first-line strategy in very high-risk patients
When diet and lifestyle are insufficient to attenuate the risk of atherosclerotic cardiovascular
disease, pharmacotherapy is mandated. A global approach that addresses multiple risk …
disease, pharmacotherapy is mandated. A global approach that addresses multiple risk …